Video

ASCRS Live: Improvements with the new CellChek 20

Robert Lin, MD, founder of IQ Laser Vision, discussed the new CellChek 20 at the 2023 ASCRS annual meeting in San Diego.

Robert Lin, MD, founder of IQ Laser Vision, discussed the new CellChek 20 at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Robert Lin, MD:

Hi, I'm Dr. Robert Lin, founder of IQ Laser Vision, also Assistant Clinical Professor at the David Geffen School of Medicine at UCLA. Today I want to talk about something really exciting. I've been performing a lot of ICL, EVO ICL, and we've been checking the endothelial cell counts, and it's been very, very difficult with the little cards.

So in the last two years, we started with the Konan version of the endothelial cell counter, which is often used in all the FDA studies when it relates to endothelial cell counts. And the older XL version was pretty good. But now we have the new CellChek 20 which actually does everything in 40 seconds, even more reproducible, and it automatically goes from one eye to the other. So in 40 seconds, we have all the information we need to safely deliver the best outcomes for our patients when they're having the EVO ICL.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.